Actively Recruiting

Age: 18Years +
All Genders
ID04650607

Phage Safety Cohort Study

Led by Hospices Civils de Lyon · Updated on 2023-04-13

100

Participants Needed

1

Research Sites

239 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are describing the side effects related to using bacteriophages to treat serious infections. This observational cohort study focuses on gathering information about these adverse events, as there is very little data currently available. The study is sponsored by Hospices Civils de Lyon and includes patients with severe infections treated with phage therapy, sometimes alongside surgery. Patients in the study receive phage injections to combat their infections. The study includes an additional biobanking component where blood samples are collected before and after phage treatment. These samples include blood, serum, and immune cells to explore if immune responses to phages contribute to any side effects. Participants provide data on any serious adverse events up to 12 months after phage injection. Blood samples are collected and stored for up to 6 months post-treatment to support immune response studies. The research team monitors and classifies adverse events to understand if they relate to surgery, antibiotics, or phages. Participants remain in the study to help gather detailed safety data over time.

CONDITIONS

Brief Title

Phage Safety Cohort Study

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient 18 years of age or older with a serious infection treated at CRIOAc Lyon by phage therapy
  • Patient who did not object to participating in the study
  • Patients having a minimum weight of 46 kg
Not Eligible

You will not qualify if you...

  • Patients under guardianship or curatorship
  • Patients deprived of liberty
  • Pregnant or breastfeeding women

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - 6 months after the injection of phages

Participants who receive phage therapy for serious infections are observed for adverse events and undergo blood sample collection for biobanking before and after treatment.

Visits for blood collection before treatment and several visits up to 6 months after treatment

Long-term Monitoring

Duration - 12 months after the injection of phages

Participants are followed for up to 12 months after phage injection to monitor the type and rate of any adverse events potentially related to treatment.

Periodic visits up to 12 months

Trial Site Locations

Total: 1 location

1

Hospices Civils de Lyon

Lyon, France, 69004

Actively Recruiting

Loading map...

Research Team

J

Johanna Boulant, CRA

T

Tristan Ferry, Md,PhD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

Antibiotic Impregnated Bone Graft to Reduce Infection in Hip...

Arthroplasty, Replacement, Hip

Actively Recruiting

1 location

Assessing the Performance of Shotgun Metagenomics in the Dia...

Prosthetic Joint Infection

Actively Recruiting

1 location

Chinese PICU Collaborative Network on Pathogens and Drug Res...

Severe Infection

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here